Neuroendokrynna regulacja masy ciała: integracja tkanki tłuszczowej, układu pokarmowego i mózgu

Human body weight is maintained at a fairly stable level regardless of changes in energy intake and energy expenditure. Compensatory mechanisms within the central nervous system (CNS), which regulate food intake and energy expenditure, are triggered by other central and peripheral signals. Peripherally, the main sources of those signals are the adipose tissue, gastrointestinal tract, and pancreas. The main signal originating from the adipose tissue is leptin, which promotes the activation of anorexigenic pathways in the CNS. Similarly, the central action of insulin also reduces food intake and stimulates catabolic pathways. The gastrointestinal tract contributes with several peptides that influence food intake, such as ghrelin, glucagon-like peptide 1 (GLP-1), peptide YY (PYY), oxyntomodulin (OXM), and cholecystokinin (CCK). Other substances secreted by the pancreas, such as pancreatic polypeptide (PP) and amylin, a hormone co-secreted with insulin, also affect energy balance. More recently, the endocannabinoid system has also been identified as a contributor in the maintenance of energy balance. Better understanding of these mechanistic systems involved in the regulation of energy metabolism will hopefully lead to the development of new therapeutic approaches against obesity, metabolic syndrome, and other nutritional disorders. (Pol J Endocrinol 2010; 61 (2): 194-206)Masa ciała człowieka jest utrzymywana na względnie stałym poziomie niezależnie od zmian zarówno w dostarczaniu energii, jak i jej zużywania. Mechanizm kompensacyjny w ośrodkowym układzie nerwowym (CNS, central nervous system [OUN]), który reguluje przyjmowanie pokarmu i wydatek energii jest uruchamiany przez inne sygnały ośrodkowe i obwodowe. Obwodowo, źródłem tych sygnałów jest tkanka tłuszczowa, układ pokarmowy i trzustka. Głównym sygnałem pochodzącym z tkanki tuszczowej jest leptyna, która powoduje aktywację anoreksogennych dróg przekazu sygnału w CNS. Podobnie, oddziaływanie ośrodkowe insuliny także zmniejsza przyjmowanie pokarmu i stymuluje kataboliczne drogi przekazu sygnału. W układzie pokarmowym współdziała kilka peptydów, które wpływają na przyjmowanie pokarmu, takie jak grelina, peptyd podobny do glukagonu (GLP-1, glucagon-like peptide), peptyd YY (PYY, peptide YY), oksyntomodulina (OXM, oxyntomodulin) i cholecystokinina (CCK, cholecystokinin), Pozostałe substancje wydzielane przez trzustkę, takie jak polipeptyd trzustkowy (PP, pancreatic polypeptide) i amylina, hormon wydzielany jednocześnie z insuliną , także wpływają na równowagę energetyczną. W najnowszych badaniach stwierdzono, że układ endokannabinoidowy przyczynia sie do zachowania równowagi energetycznej. Lepsze zrozumienie mechanizmów układów wpływających na regulacje przemiany energii przyczyni się do rozwoju nowych terapii otyłości, zespołu metabolicznego i innych zaburzeń odżywiania. (Endokrynol Pol 2010; 61 (2): 194-206

Revisitando a síndrome de Nelson

A síndrome de Nelson é caracterizada pela tríade de hiperpigmentação cutânea, níveis elevados de ACTH e expansão do tumor hipofisário após adrenalectomia bilateral como terapia para Doença de Cushing. Apresenta taxas de incidência que variam de 0 a 47% e tem como principais fatores preditivos para o seu surgimento os níveis de ACTH plasmático no primeiro ano após a adrenalectomia, duração da doença de Cushing até a retirada das adrenais e tratamento prévio com radioterapia para o tratamento da doença de Cushing. Os critérios diagnósticos para essa doença consistem na adrenalectomia bilateral em pacientes com doença de Cushing associada à elevação nos níveis de ACTH (acima de 500 ng/L ou aumento de pelo menos 30% do valor em três amostras consecutivas) e/ou imagem hipofisária com lesão tumoral. O tratamento de primeira linha é a ressecção da lesão através da cirurgia transesfenoidal, porém radioterapia e tratamento farmacológico com cabergolina, pasireotide ou temozolamida podem ser necessários em alguns casos

Revisitando a síndrome de Nelson

A síndrome de Nelson é caracterizada pela tríade de hiperpigmentação cutânea, níveis elevados de ACTH e expansão do tumor hipofisário após adrenalectomia bilateral como terapia para Doença de Cushing. Apresenta taxas de incidência que variam de 0 a 47% e tem como principais fatores preditivos para o seu surgimento os níveis de ACTH plasmático no primeiro ano após a adrenalectomia, duração da doença de Cushing até a retirada das adrenais e tratamento prévio com radioterapia para o tratamento da doença de Cushing. Os critérios diagnósticos para essa doença consistem na adrenalectomia bilateral em pacientes com doença de Cushing associada à elevação nos níveis de ACTH (acima de 500 ng/L ou aumento de pelo menos 30% do valor em três amostras consecutivas) e/ou imagem hipofisária com lesão tumoral. O tratamento de primeira linha é a ressecção da lesão através da cirurgia transesfenoidal, porém radioterapia e tratamento farmacológico com cabergolina, pasireotide ou temozolamida podem ser necessários em alguns casos

Recommendations of the neuroendocrinology department of the Brazilian society of endocrinology and metabolism for the diagnosis of Cushing’s disease in Brazil

Although it is a rare condition, the accurate diagnosis and treatment of Cushing’s disease is important due to its higher morbidity and mortality compared to the general population, which is attributed to cardiovascular diseases, diabetes mellitus and infections. Screening for hypercortisolism is recommended for patients who present multiple and progressive clinical signs and symptoms, especially those who are considered to be more specific to Cushing’s syndrome, abnormal findings relative to age (e.g., spinal osteoporosis and high blood pressure in young patients), weight gain associated with reduced growth rate in the pediatric population and for those with adrenal incidentalomas. Routine screening is not recommended for other groups of patients, such as those with obesity or diabetes mellitus. Magnetic resonance imaging (MRI) of the pituitary, the corticotropin-releasing hormone (CRH) test and the high-dose dexamethasone suppression test are the main tests for the differential diagnosis of ACTH-dependent Cushing’s syndrome. Bilateral and simultaneous petrosal sinus sampling is the gold standard method and is performed when the triad of initial tests is inconclusive, doubtful or conflicting. The aim of this article is to provide information on the early detection and establishment of a proper diagnosis of Cushing’s disease, recommending follow-up of these patients at experienced referral centers

Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil

A acromegalia é uma doença associada à elevada morbidade e à redução da expectativa de vida. Em virtude do seu caráter insidioso e do seu não reconhecimento, o diagnóstico é frequentemente realizado com atraso, o que, associado às complicações relacionadas ao excesso do GH/IGF-I, determina elevada morbimortalidade. No entanto, um diagnóstico precoce e um tratamento efetivo minimizam a morbidade e normalizam a taxa de mortalidade. Nesta publicação, o objetivo do Departamento de Neuroendocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia é divulgar quando suspeitar clinicamente da acromegalia e como diagnosticá-la. Além disso, discute-se a maneira mais eficaz e segura de realizar o tratamento da acromegalia, enfatizando que este deve ser realizado em centros de referência. Assim, com base em dados publicados em periódicos de nível científico reconhecido e na experiência dos autores, são apresentadas as recomendações para o diagnóstico e tratamento da doença.Acromegaly is a disease associated with increased morbidity and reduced life expectancy. Because of its insidious character and its non-recognition, the diagnosis is often made with delay, which, along with the complications related to GH/IGF-I excess, determines high morbidity and mortality. However, an early diagnosis and an effective treatment reduce the morbidity and normalize the mortality rate. In this publication, the goal of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism is to disclose which clinical set should arouse the suspicious of acromegaly and how to diagnose it. Furthermore, we discuss the most effective and safe approach to perform the treatment of acromegaly, emphasizing that it must be carried out in reference centers. Therefore, based on data published in journals with recognized scientific level and authors' experience, recommendations are presented for diagnosis and treatment of the disease

Sarcopenia in COPD: relationship with COPD severity and prognosis

Objective: To evaluate the prevalence of sarcopenia in COPD patients, as well as to determine whether sarcopenia correlates with the severity and prognosis of COPD. Methods: A cross-sectional study with COPD patients followed at the pulmonary outpatient clinic of our institution. The patients underwent dual-energy X-ray absorptiometry. The diagnosis of sarcopenia was made on the basis of the skeletal muscle index, defined as appendicular lean mass/height2 only for low-weight subjects and adjusted for fat mass in normal/overweight subjects. Disease severity (COPD stage) was evaluated with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The degree of obstruction and prognosis were determined by the Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity (BODE) index. Results: We recruited 91 patients (50 females), with a mean age of 67.4 ± 8.7 years and a mean BMI of 25.8 ± 6.1 kg/m2. Sarcopenia was observed in 36 (39.6%) of the patients, with no differences related to gender, age, or smoking status. Sarcopenia was not associated with the GOLD stage or with FEV1 (used as an indicator of the degree of obstruction). The BMI, percentage of body fat, and total lean mass were lower in the patients with sarcopenia than in those without (p < 0.001). Sarcopenia was more prevalent among the patients in BODE quartile 3 or 4 than among those in BODE quartile 1 or 2 (p = 0.009). The multivariate analysis showed that the BODE quartile was significantly associated with sarcopenia, regardless of age, gender, smoking status, and GOLD stage. Conclusions: In COPD patients, sarcopenia appears to be associated with unfavorable changes in body composition and with a poor prognosis